Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights August 5, 2026 Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to be a blockbuster opportunity, if approved Rolling NDA submission and initial review underway and final submission expected to be completed in Q4 Commercial launch expected in first half of 2027 COMP360 expected to fit seamlessly into current treatment infrastructure Late-stage PTSD trial underway Strong cash position of $433 million at the end of second quarter, providing cash well beyond launch and into 2028 Compass management will host a conference call on August 5 at 8:00 am ET
IFF Reports Second Quarter 2026 Results; Announces Use of Proceeds Plan for Food Ingredients Divestiture August 4, 2026 Delivered Strong Sales, Profit and Cash Flow Performance in Second Quarter 2026 Provides Full Year 2026 Financial Guidance on a Continuing Operations Basis Announces Enhanced $2.5B Share Repurchase Authorization; Including $500M Accelerated Share Repurchase in the second half of 2026
IGI Reports Second Quarter and First Six Months of 2026 Unaudited Financial Results and Declares Ordinary Common Share Dividend August 4, 2026 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the second quarter and first six months of 2026. Highlights for the second quarter and first six months of 2026 include: (in millions of U.S. Dollars, except percentages and per share information) Quarter Ended June 30, Six Months [...]
Techtronic Industries Delivers Strong First Half Performance August 4, 2026 Growing Sales to US$8.3 Billion, Net Profit Increased to US$738 Million
Vedanta Aluminium Reports Record Q1 FY27 Performance; Profit Surges 205%, EBITDA More Than Doubles August 2, 2026 Vedanta Aluminium Metal Limited (NSE: VAML, BSE: 544780), one of the world’s leading aluminium producers, today announced record financial results for the quarter ended June 30, 2026, marking a strong debut as an independent listed company following its demerger. The Board of Directors approved the company’s first interim dividend of INR 8 per equity share, [...]
Smurfit Westrock plc: Form 10-Q for the Quarterly Period Ended June 30, 2026 July 31, 2026 Today Smurfit Westrock plc (the “Company”) filed its quarterly report on Form 10-Q for the quarterly period ended June 30, 2026 with the U.S Securities and Exchange Commission (the “SEC”). The Form 10-Q is available to view on the SEC’s website at: https://www.sec.gov and the Company’s website at: https://investors.smurfitwestrock.com/financials/sec-filings/default.aspx View source version on businesswire.com: https://www.businesswire.com/news/home/20260731145091/en/ [...]
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 2026 July 31, 2026 Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billion Global expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in Italy TIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital
AngloGold Ashanti Q2 30 June 2026 Earnings Release and Dividend Declaration July 31, 2026 Q2 2026 EBITDA*(5) +46% to $2.0bn • Q2 2026 free cash flow* +36% to $727m • YTD free cash flow* $1.9bn • Q2 2026 interim dividend of $364m, or 72 cps • Proposed $2.0bn share repurchase programme approved • Net cash*(5) of $991m after debt buyback
Prothena to Report Second Quarter 2026 Financial Results on August 6 July 30, 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, after the close of the U.S. financial markets. Consistent with past practice, [...]
De’ Longhi Group: a Quarter of Robust Revenue Growth of 8.4% and Solid Margin Expansion Drives an Upward Guidance Revision July 30, 2026 Substantial expansion in Professional and acceleration in Household drive growth and margins, enabling further investments in marketing and product innovation as part of the Group's continuous strategic evolution